In conclusion, to our best knowledge, this is the first study to show that patients with ACS and concomitant UCOPD have increased endothelial dysfunction and on-treatment platelet reactivity. Moreover, we showed that ticagrelor may contribute to improve both parameters. Accordingly, any further effort for early identification and treatment of patients with UCOPD should be encouraged.
Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial
PAVASINI, Rita
Primo
;VIECELI DALLA SEGA, Francesco;GALLO, Francesco;Passarini, Giulia;PAPI, Alberto;CONTOLI, Marco;CAMPO, Gianluca Calogero
2017
Abstract
In conclusion, to our best knowledge, this is the first study to show that patients with ACS and concomitant UCOPD have increased endothelial dysfunction and on-treatment platelet reactivity. Moreover, we showed that ticagrelor may contribute to improve both parameters. Accordingly, any further effort for early identification and treatment of patients with UCOPD should be encouraged.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
